<DOC>
	<DOC>NCT01279850</DOC>
	<brief_summary>The objective of this investigation is to evaluate the safety and efficacy of long term use with Lyrica in medical practice. Also, occurrence of unknown and known adverse drug reactions (ADRs) in subjects treated with Lyrica will be monitored during the survey period, and whether an additional treatment outcome investigation and/or a post-marketing clinical study is required in the future will be determined.</brief_summary>
	<brief_title>Safety And Efficacy In Long Term Use Of Lyrica (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description>Patients who fulfill criteria below: 1. Patients who have previously enrolled in A0081261. 2. Patients who have been administered Lyrica for more than 52 weeks.</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Patients need to be administered by Lyrica for over 52 weeks in order to be enrolled in the surveillance. Patients not administered Lyrica.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Lyrica</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan</keyword>
	<keyword>Safety</keyword>
	<keyword>Neuropathic Pain</keyword>
	<keyword>Post Marketing Surveillance</keyword>
</DOC>